icon-folder.gif   Conference Reports for NATAP  
 
  The Liver Meeting
Digital Experience
AASLD
Washington on 04-08
November 2022
Back grey_arrow_rt.gif
 
 
 
Hepatocellular Carcinoma: State of the Art - missing is
& Post HCV Cure Surveillance in Patients with Cirrhosis !

 
 
  AASLD nov 4-8 2022

1121221

1121222

We need NOW to be aggressive about prevention, early detection & treatment.
 
we see a rising mortality rate in men & women, one of the few cancers in which we see this. If these trends continue HCC is projected to be 3rd leading cause of death by 2035.

1121223

the AT RISK POPULATION we need to target are those with cirrhosis OR at risk for cirrhosis.
 
BUT there is some risk to get HCC without having cirrhosis in HBV & NASH. But only in HBV do we recommend HCC screening without having first cirrhosis.
 
Cirrhosis creates an identifiable at-risk population.

1121224

EARLY DETECTION IS KEY TO SURVIVAL

1121225

IMPORTANCE OF SCREENING
 
#! patients with CIRRHOSIS cured by DAAs who are SILL at risk for HCC & MUST continue regular screening BUT do NOT - we see years later many of these patients coming up with large HCCs no longer treatable. ULTRASOUND + AFP - this is new recommendation in GUidance for this group for continued surveillance.
 
Many prefer using MRI instead of ultrasound, they think its BETTER.

1121226

25% of patients with cirrhosis are screened

1121227

1121228

1121229